Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

[1]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[2]  D. Cunningham,et al.  Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. , 2014, The Lancet. Oncology.

[3]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Ajani,et al.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[6]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[7]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[8]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Joon-Oh Park,et al.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[12]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[13]  K. Matsuo,et al.  Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. Heldin,et al.  Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer , 2010, BMC Cancer.

[15]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[16]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[18]  Joon-Oh Park,et al.  A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer , 2009, BMC Cancer.

[19]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Kodera,et al.  A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). , 2007, Anticancer research.

[21]  B. Pestalozzi,et al.  Molekular zielgerichtete Therapie , 2006, Der Chirurg.

[22]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Vieth,et al.  Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Yoshino,et al.  Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer , 2006, Gastric Cancer.

[25]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[26]  L. Ellis,et al.  Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. , 2002, European journal of cancer.

[27]  S. Tanabe,et al.  [Advanced gastric cancer]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[28]  S. Cascinu,et al.  Phase II study of paclitaxel in pretreated advanced gastric cancer , 1998, Anti-cancer drugs.

[29]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[31]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[32]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[33]  David L. DeMets,et al.  Asymmetric group sequential boundaries for monitoring clinical trials , 1982 .